Literature DB >> 12574332

Epitope spreading is not required for relapses in experimental autoimmune encephalomyelitis.

Richard E Jones1, Dennis Bourdette, Nicole Moes, Arthur Vandenbark, Alex Zamora, Halina Offner.   

Abstract

The sequential emergence of specific T lymphocyte-mediated immune reactivity directed against multiple distinct myelin epitopes (epitope spreading) has been associated with clinical relapses in experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS). Based on this association, an appealing and plausible model for immune-mediated progression of the advancing clinical course in MS and EAE has been proposed in which epitope spreading is the cause of clinical relapses in T cell-mediated CNS inflammatory diseases. However, the observed association between epitope spreading and disease progression is not universal, and absolute requirements for epitope spreading in progressive EAE have not been tested in the absence of multiple T cell specificities, because most prior studies have been conducted in immunocompetent mouse strains that possessed broad TCR repertoires. Consequently, the precise nature of a causal relationship between epitope spreading and disease progression remains uncertain. To determine whether relapsing or progressive EAE can occur in the absence of epitope spreading, we evaluated the course of disease in mice which possessed only a single myelin-specific TCR. These mice (transgenic/SCID +/+) exhibited a progressive and sometimes remitting/relapsing disease course in the absence of immune reactivity to multiple, spreading myelin epitopes. The results provide direct experimental evidence relevant to discussions on the mechanisms of disease progression in MS and EAE.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12574332     DOI: 10.4049/jimmunol.170.4.1690

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Progression of relapsing-remitting demyelinating disease does not require increased TCR affinity or epitope spread.

Authors:  Anna E Kersh; Lindsay J Edwards; Brian D Evavold
Journal:  J Immunol       Date:  2014-09-29       Impact factor: 5.422

2.  T cells that trigger acute experimental autoimmune encephalomyelitis also mediate subsequent disease relapses and predominantly produce IL-17.

Authors:  Jinzhu Li; Xiaoqing Zhao; Hui-Wen Hao; Michael K Shaw; Harley Y Tse
Journal:  J Neuroimmunol       Date:  2010-09-09       Impact factor: 3.478

3.  Role of pathogenic T cells and autoantibodies in relapse and progression of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis in LEW.1AV1 rats.

Authors:  Yoh Matsumoto; Il-Kwon Park; Keiko Hiraki; Shin Ohtani; Kuniko Kohyama
Journal:  Immunology       Date:  2008-10-29       Impact factor: 7.397

4.  Treatment of experimental autoimmune encephalomyelitis with alpha lipoic acid and associative conditioning.

Authors:  Richard E Jones; Nicole Moes; Heather Zwickey; Christopher L Cunningham; William L Gregory; Barry Oken
Journal:  Brain Behav Immun       Date:  2007-12-26       Impact factor: 7.217

Review 5.  Molecular pathogenesis of neuroinflammation.

Authors:  M Bradl; R Hohlfeld
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-10       Impact factor: 10.154

6.  Lymphocytes with aberrant expression of Fas or Fas ligand attenuate immune bone marrow failure in a mouse model.

Authors:  Stephanie O Omokaro; Marie J Desierto; Michael A Eckhaus; Felicia M Ellison; Jichun Chen; Neal S Young
Journal:  J Immunol       Date:  2009-03-15       Impact factor: 5.422

7.  Recombinase-activating gene 1-associated expression of the myelin basic protein 1-11-specific transgenic T-cell receptor in H-2b mice.

Authors:  Abigail C Buenafe; Courtney Sherwood; Nicole Moes; Richard E Jones
Journal:  J Neurosci Res       Date:  2009-01       Impact factor: 4.164

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.